MINDACT Trial: Outcome of Patients with UltraLow Risk, JCO 2022
Journal of Clinical Oncology, Volume 40, Number 12, January 21, 2022 Authors: Audeh et al.
Read MoreDurvalumab + olaparib + paclitaxel in High-risk HER2-negative ESBC: I-SPY2 trial results
I-SPY2 Trial, Cancer Cell 39, 989โ998, 2021 Authors: Pusztai et al.
Read MoreMolecular profiles of genomically High Risk ER+ HER2- breast cancer tumors classified as functionally Basal or Luminal B by the BluePrint
PUBLICATION: ASCO 2021 ย Authors Joyce OโShaughnessy1, Virginia G. Read More
Whole transcriptome analysis comparing HR+ HER2- breast cancer tumors from patients โค 50 years and > 50 years
PUBLICATION: ASCO 2021 ย Authors Cathy Graham1, Douglas K. Read More
Gene expression associated with lymphovascular invasion and genomic risk in early-stage breast cancer
PUBLICATION: ASCO 2021 Authors Nina DโAbreo1,2, Abhinav Rohatgi1,2, Douglas Read More
B-42 Trial: MammaPrint Utility for Prediction of Extended Letrozole Therapy, ASCO 2021
NSABP B-42 Trial, ASCO 2021 Abstract #502 Authors: Rastogi, et al.
Read MoreMammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles (FLEX): A real-world dataset and investigator-initiated protocols in ESBC
ย Publication: St. Gallen Authors: Jennifer A. Crozier, Lisa Blumencranz, Read More
5-year distant metastasis-free survival outcomes on the pre-operative use of MammaPrint and BluePrint for neoadjuvant decisions in the NBREaST II trial
Publication: St. Gallen Authors: E. Gรถker, M.P. Hendriks, M. van Read More
Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens
Publication: St Gallen ย Authors: M. Kleijn, J. McKelley, Read More
Pathologic Complete Response (pCR) Rates According to MammaPrint and BluePrint Results are Consistent Among Pre- and Post-Menopausal Patients
ย Publication: Miami Breastย Authors Pat Whitworth, James Read More
